DrugDashboards

Bryhali

halobetasol propionate · HALOBETASOL PROPIONATE .1 mg/g · Lotion · Topical · Bausch Health US, LLC

NDC 00187-0002-01 · 1 TUBE in 1 CARTON / 100 g in 1 TUBE · NDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $5.11 per gram over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$5.11per GMinvoice-surveyed acquisition cost · Sep 17, 2025
  • Part D plans paid (avg)$5.24per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00187-0002-60) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$5.50per unit
middle half $5.50$6.07 · 29 plans · Jul 1, 2024
Est. net of rebates
$3.30–$4.12
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Apr 2020Sep 2025$5.11
16 price points · per GM · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$566.95
Reported to Texas DSHS · 2026 annual filing · Bausch Health US, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for halobetasol propionate (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA209355
TE code
Approval date
Nov 6, 2018
Patents / exclusivity
6 patents, 0 exclusivities
TypeNumber / codeExpires
patent10478502Nov 2, 2031
patent11986527Nov 2, 2031
patent11839656Nov 2, 2031
patent11957753Nov 2, 2031
patent12076403Nov 2, 2031
patent8809307Nov 2, 2031

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of halobetasol propionate (Lotion)

LabelerStrengthFirst seenLast seen
Bausch Health US, LLCHALOBETASOL PROPIONATE .1 mg/gJul 15, 2026Sep 2, 2026
Coral Way Pharma, LLCHALOBETASOL PROPIONATE .5 mg/gJul 15, 2026Sep 2, 2026
Lacer Pharma, LLCHALOBETASOL PROPIONATE .5 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bryhali — NDC 00187-0002-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00187000201.

Free to cite with attribution — see how the data is put together.